A federal judge has blocked a Colorado state panel from capping the price of Amgen's blockbuster drug Enbrel. The decision halts the state's first-of-its-kind effort to control pharmaceutical costs through direct price controls. Legal experts say the ruling could set a precedent for similar initiatives nationwide.
The Colorado panel had sought to limit how much the drugmaker could charge for Enbrel, a widely used treatment for autoimmune diseases. Proponents argued the cap was necessary to address soaring drug costs that burden patients and insurers. Amgen contested the move, asserting it violated federal law and patent protections.
Enbrel is one of Amgen's top-selling products, generating billions in annual revenue. Specific pricing data from the sources remains unavailable. The judge's order temporarily prevents enforcement while the case proceeds.
The pharmaceutical industry views the ruling as a key victory against state-level price regulation. Patient advocacy groups, however, warn the decision could undermine efforts to make medications more affordable. Colorado officials may appeal or pursue alternative pricing mechanisms.
Critics note that price caps risk stifling innovation by reducing revenue streams for research. They argue market-based solutions offer a more sustainable path to lowering costs without legal battles.